Oruka Therapeutics Inc (ABIO)

What analysts predicted

Upside of 191.67%

• Cable Car Capital LLC

  27.58%

• Western Standard LLC

  9.72%

• RTW INVESTMENTS, LLC

  9.65%

• HHG PLC

  9.53%

• Adage Capital Partners Gp LLC

  8.27%

• Vanguard Group Inc

  3.13%

arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.